Document is current

Article History

Received: 5 January 2022

Accepted: 21 November 2022

First Online: 6 December 2022

Declarations

:

: Not available.

: Not available.

: Vipul Jairath has received consulting/advisory board fees from AbbVie, Alimentiv Inc. (formerly Robarts Clinical Trials), Arena Pharmaceuticals, Asieris Pharmaceuticals, Bristol Myers Squibb, Celltrion Healthcare, Eli Lilly and Company, Ferring Pharmaceuticals, Fresenius Kabi, Galapagos, GlaxoSmithKline, Genentech, Gilead Sciences, Janssen, Merck, Mylan, Pandion Therapeutics, Pendopharm, Pfizer, Reistone Biopharma, Roche, Sandoz, Takeda, and TopiVert; and speaker’s fees from AbbVie, Ferring Pharmaceuticals, Galapagos, Janssen, Pfizer, Shire, and Takeda. Russell D. Cohen has received consulting fees from AbbVie, BMS/Celgene, Eli Lilly and Company, Gilead Sciences, Janssen, Pfizer, Takeda, and UCB; speaker’s fees from AbbVie and Takeda; and serves as a principal investigator for or has received grants from AbbVie, BMS/Celgene, Boehringer Ingelheim, Crohn’s & Colitis Foundation, Genentech, Gilead Sciences, Hollister, MedImmune, Mesoblast Ltd., Osiris Therapeutics, Pfizer, Receptos, RedHill Biopharma, Sanofi-Aventis, Schwarz Pharma, Seres Therapeutics, Takeda, and UCB. Edward V. Loftus Jr. has received consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Bristol Myers Squibb, Boehringer Ingelheim, Calibr, Celgene, Eli Lilly and Company, Genentech, Gilead Sciences, Gossamer Bio, Iterative Scopes, Janssen, Morphic, Ono Pharmaceutical, Protagonist, Pfizer, Scipher Medicine, Sun Pharma, Surrozen, Takeda, and UCB; and research support from AbbVie, Bristol Myers Squibb, Celgene, Genentech, Gilead Sciences, Gossamer Bio, Janssen, Pfizer, Receptos, Robarts Clinical Trials, Takeda, Theravance, and UCB. Ninfa Candela, Karen Lasch, and Bob G. Schultz are employees of Takeda Pharmaceuticals U.S.A., Inc., and have stock or stock options.